Esomeprazole Magnesium Capsule, Delayed Release Pellets
Product Images NDC 62175-820

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 62175-820). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Esomeprazole Magnesium Delayed Release Capsules Us 1)

Chemical structure of Esomeprazole Magnesium, showing the molecular arrangement with magnesium ion and two water molecules as part of the compound.*

FDA Label Image

Figure 2: Maintenance Of Healing Rates By Month (study 177) (Esomeprazole Magnesium Delayed Release Capsules Us 2)

This line graph depicts the percentage of drug retained over a six-month period for Esomeprazole Magnesium delayed-release capsules at 10 mg, 20 mg, and 40 mg doses compared with a placebo. The x-axis represents months, including scheduled visits, and the y-axis represents the percent maintained of the drug. The 40 mg dose shows the highest retention, followed by 20 mg, 10 mg, and placebo over time.*

FDA Label Image

Figure 3: Maintenance Of Healing Rates By Month (study 178) (Esomeprazole Magnesium Delayed Release Capsules Us 3)

A line graph showing the percentage of drug amount maintained over 6 months for Esomeprazole Magnesium delayed-release capsules at 10 mg, 20 mg, and 40 mg strengths, compared to a placebo. The x-axis represents months with scheduled visits; the y-axis shows percent maintained. Data points show higher maintenance rates for 20 mg and 40 mg doses compared to 10 mg and placebo groups.*

FDA Label Image

Figure 4 (Esomeprazole Magnesium Delayed Release Capsules Us 4)

A line graph showing the percent of patients symptom-free over 28 diary days for Esomeprazole Magnesium delayed-release capsules 20 mg and 40 mg strengths compared to placebo. The percent of symptom-free patients increases over time for both strengths, with the 40 mg line generally higher than the 20 mg, and both above placebo throughout the period.*

FDA Label Image

Figure 5 (Esomeprazole Magnesium Delayed Release Capsules Us 5)

A line graph depicting the percent of patients symptom-free over a 28-day diary period. It compares Esomeprazole Magnesium delayed-release capsules 40 mg, 20 mg, and placebo groups, showing symptom-free percentages on the y-axis and diary days on the x-axis. The 40 mg and 20 mg doses show higher symptom-free percentages compared to placebo.*

FDA Label Image

20 mg 30 Count (Esomeprazole Magnesium Delayed Release Capsules Us 6)

Packaging label for Esomeprazole Magnesium 20 mg delayed-release capsules, USP, distributed by Lannett Company, Inc. The label indicates a 30-capsule count and includes storage instructions and a medication guide URL. The NDC is 62175-820-32.*

FDA Label Image

40 mg 30 Count (Esomeprazole Magnesium Delayed Release Capsules Us 7)

Label for Esomeprazole Magnesium delayed-release capsules, USP, 40 mg strength. The label states the product contains 30 capsules and is distributed by Lannett Company, Inc., Philadelphia, PA. It also includes storage instructions and a barcode on the left side. The design features a white background with purple and black text and the Lannett logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.